Is Club Drug Answer for Treatment-Resistant Depression?

With many people suffering from depression not responding to antidepressants despite trying several, there is a critical need for therapies that can treat what is known as treatment-resistant depression. Although it might sound unusual, a medication derived from what is best known as a party drug might just be what millions of people have been looking for.

The drug, esketamine, is closely related to ketamine, a legal anesthetic used in both humans and animals, though it is most popularly known as a party drug due to its hallucinogenic effects. Johnson & Johnson’s Janssen division developed esketamine, which is designed as a nasal spray. The company says the drug is a fast-acting therapy for treatment-resistant depression. While traditional antidepressants can take weeks or months to have any positive effect – if any at all – many people who have taken esketamine report feeling better within a matter of hours.

To me, there is an essential need for a drug like esketamine. About one-third of adults with major depression don’t respond to antidepressants. Given that major depression affects more than 16 million adult Americans – about 6.7% of the US population 18 and older – each year, that’s more than 5 million people who could benefit from esketamine.

As we previously reported in MedShadow, there are plenty of clinics that have popped up across the country offering straight ketamine infusions. The infusions are not cheap, and their efficacy is debatable.

An FDA advisory committee will discuss esketamine at a meeting today, and their decision could well determine if esketamine will ever hit the market. While the FDA is not bound by an advisory committee vote, it usually follows their guidance in making approval decisions.

The FDA is set to render a decision on esketamine on or before March 4. Although the drug has “breakthrough-therapy” designation — meaning it has an expedited review because it treats a serious or life-threatening illness or it represents a significant improvement over existing treatments — that’s not a guarantee a majority of FDA panel members will agree it should be approved.

That’s because of some concerns. The first, which was brought up by FDA staff in review documents, is the potential for abuse, though they admitted this is low and can be mitigated. The other is that since esketamine can cause dissociation, the hallucinogenic feeling I mentioned before, some people who take it could be at risk for accidents or other kinds of harm. Some people have reported this feels like an “out of body” experience. In two late-stage studies, about 27.4% of people taking esketamine experienced dissociation. FDA reviewers say dissociation takes about 90 minutes to go away. That will likely weigh on the minds of many committee members.

There’s also a question about efficacy. In one phase 3 trial, in which patients were given either esketamine plus an antidepressant or a placebo plus antidepressant, there was no difference in change in depression severity between the two groups over four weeks. However, in two other phase 3 trials, the time to relapse of depressive symptoms was slower in the esketamine plus antidepressant group as opposed to the placebo plus antidepressant group.

Esketamine is also under investigation as a treatment for depressed people at heightened risk of suicide. Given that the nation’s suicide rate increased 33% between 1999 and 2017, according to Centers for Disease Control and Prevention data, esketamine could potentially play a role in reversing that trend.

As I see it, the potential benefits of esketamine outweigh some of its concerns. While I don’t believe it will be a solution for everyone suffering from treatment-resistant depression, it could represent the first depression treatment with a new method of action in decades. Given the toll depression and suicides take on society, the FDA should give doctors another treatment option.

Jonathan Block

Jonathan Block

Jonathan Block is an associate editor at BioCentury, which provides news and information about the biotechnology and pharmaceutical industries. Prior to joining BioCentury in 2019, Jonathan worked for MedShadow as content editor. He has been an editor and writer for multiple pharmaceutical, health and medical publications, including The Pink Sheet, Modern Healthcare, Health Plan Week and Psychiatry Advisor. He holds a BA from Tufts University and is earning an MPH with a focus on health policy from the CUNY Graduate School of Public Health & Health Policy.

Did you find this article helpful?

Latest News

Breaking News – EpiPen Malfunction

Breaking News – EpiPen Malfunction

Just released from the FDA – Pfizer has informed the FDA that they are aware of several continuing problems that people are having using the EpiPen (epinephrine) and EpiPen Jr (epinephrine) auto-injectors and generic versions. Some of the problems are from user error and some from EpiPen malfunction. Here are…

ACE Inhibitors in the Time of Coronavirus

ACE Inhibitors in the Time of Coronavirus

Are you worried about ACE inhibitors and coronavirus? You may be hearing that one of the entry methods for the coronavirus in humans is by attaching to the ACE-2 enzyme. This has raised alarms among those with heart disease who use ACE inhibitors (with names ending in -pril, such as…

  • Advertisement